Glossary Entry

Post-Marketing Surveillance

Post-marketing surveillance is the ongoing review of safety and use information once a medicine is available in the market.

Definition

Post-marketing surveillance refers to the activities used to monitor a medicine after approval and commercial availability. This includes tracking reports, reviewing safety information, and assessing whether new evidence affects the balance between benefits and risks.

It is a continuation of the safety oversight work started during development but applied in the real-world context of patient use. The objective is to identify issues that may not have been apparent before launch and to ensure that oversight remains active as more information becomes available.

Why It Matters

Post-marketing surveillance is a key part of lifecycle safety management. It supports the detection of emerging concerns, informs risk evaluation, and helps organizations remain prepared for regulatory questions or evolving clinical understanding.

For many organizations, this area is closely connected to pharmacovigilance, signal detection, and aggregate reporting. It plays a practical role in maintaining confidence in safety oversight long after approval.

How It Relates to MedNova

MedNova supports teams that need a clear and dependable approach to post-approval monitoring. Our work helps structure processes so that safety information is reviewed consistently and translated into actionable oversight.

This includes support for organizations that need to strengthen reporting discipline, coordinate cross-functional review, and connect surveillance work with broader pharmacovigilance and compliance needs.

Frequently Asked Questions

What is Post-Marketing Surveillance?

It is the ongoing oversight of a product after approval to detect new information that may affect its safety profile or benefit-risk balance.

How is it different from clinical trials?

Clinical trials mainly evaluate a product before approval, while post-marketing surveillance monitors its performance and safety in broader, real-world use.

Why is it important?

Because it helps organizations stay responsive to new evidence and maintain reliable safety monitoring over the product lifecycle.

Need expert support?

MedNova can help organizations strengthen post-approval monitoring processes and connect safety review with practical regulatory planning.

Book a Consultation
Practical next step: For teams that want to turn this guidance into action, MedNova offers training and consulting and a downloadable checklist PDF that help connect regulatory readiness, safety, and documentation practices.